Penicillin kills bacteria by disabling the machinery that builds and maintains their cell wall, specifically the rigid mesh of peptidoglycan that keeps a bacterium from bursting under its own internal pressure. The drug does this through a clever bit of molecular mimicry, pretending to be a normal building block of the wall and jamming the enzymes that stitch the wall together. The result is a weakened structure that cannot hold up against the forces inside the cell, and the story of how that plays out is more layered than most people realize.
Peptidoglycan, the Wall’s Load-Bearing Scaffold
Bacterial cell walls are not simple membranes. They contain a thick, net-like polymer called peptidoglycan, which acts as the structural skeleton of the cell. Peptidoglycan is made of alternating sugar units linked together into long chains, and those chains are connected to one another by short peptide bridges. The cross-linking of those bridges is what gives the wall its rigidity and mechanical strength.1PubMed Central. Three-dimensional structure of the bacterial cell wall peptidoglycan Without that cross-linking, the wall is just loose strands of sugar with no structural integrity.
The amount of peptidoglycan varies depending on the type of bacterium. In Gram-positive species, peptidoglycan can account for roughly half the weight of the cell wall. In Gram-negative species, the layer is thinner, making up about 10 to 20 percent of the envelope.2Molecular Medical Microbiology. Antibiotics that Act on the Cell Wall and Membrane Either way, peptidoglycan is essential. Remove it, weaken it, or prevent its assembly, and the bacterium is in serious trouble.
How Penicillin Fools the Cell’s Own Enzymes
The cross-linking step in peptidoglycan assembly is carried out by a family of enzymes called penicillin-binding proteins, or PBPs. These enzymes recognize a specific sequence at the end of the peptide stems dangling off the sugar chains and use it to stitch neighboring chains together. The key recognition sequence is a pair of amino acids called D-alanyl-D-alanine, which sits at the tip of each peptide stem like a handle waiting to be grabbed.
Penicillin’s secret is that its core chemical structure, the beta-lactam ring, closely resembles that D-alanyl-D-alanine handle. When a PBP reaches for what it thinks is its normal substrate, it grabs penicillin instead.3PubMed Central. Structural Insights for β-Lactam Antibiotics The drug then reacts with the enzyme’s active site and forms an extremely stable bond. Instead of the normal quick-release interaction the enzyme expects, penicillin locks on and does not let go. The enzyme is effectively jammed in an “occupied” state, unable to process any more peptide stems.4PubMed. Structures of two kinetic intermediates reveal species specificity of penicillin-binding proteins
This is sometimes described as penicillin acting as a “steric analogue” of the natural substrate, forming a penicilloyl-enzyme complex that the enzyme cannot shake off.5Annual Reports in Medicinal Chemistry. Bacterial Penicillin-Binding Proteins The practical upshot is simple: the cross-links never form, and the growing wall is left full of gaps.
What Penicillin-Binding Proteins Actually Do
PBPs are not just one enzyme doing one job. They are a family of enzymes with multiple roles in wall assembly. Two of the most important activities are transpeptidation, which creates the cross-links between peptidoglycan chains, and carboxypeptidation, which trims excess amino acids from the peptide stems to regulate how many cross-links form.6PubMed. A mechanism-based inhibitor targeting the DD-transpeptidase activity of bacterial penicillin-binding proteins Both activities use the same kind of active site, and both can be blocked by penicillin.
A single bacterial species typically has several different PBPs, and they are not all equally important. Some are essential for survival, while others play backup or specialized roles. This is why different beta-lactam antibiotics can have different effects even though they all target PBPs: depending on which PBPs a given drug binds most tightly, the downstream consequences for the bacterium can vary. Crystal structures of PBPs from disease-causing bacteria have shown that some beta-lactams can slot into the active site without the enzyme needing to change shape at all, which helps explain why certain drugs are so effective.7PubMed Central. Crystal structures of bifunctional penicillin-binding protein 4 from Listeria monocytogenes
From Weak Walls to Bursting Cells
Blocking PBPs does not kill a bacterium instantly. What happens next is a cascade. As the cell tries to grow and divide, it keeps making new peptidoglycan sugar chains, but those chains are not being cross-linked properly. The wall develops structural weak points. Meanwhile, the cell’s internal pressure, generated by the high concentration of dissolved molecules inside, keeps pushing outward. Eventually the wall cannot resist, and the cell ruptures. This explosive lysis is the classic mode of penicillin-induced death.8Nature Communications. On the mechanisms of lysis triggered by perturbations of bacterial cell wall biosynthesis
But lysis is not purely a passive mechanical failure. Bacteria carry their own wall-degrading enzymes called autolysins, which normally break down small sections of the wall in a controlled way to allow the cell to expand and divide. When penicillin disrupts wall synthesis, these autolysins can become deregulated and start chewing through the wall faster than it can be repaired. In pneumococci, for instance, a specific autolysin has been shown to drive the lysis that follows penicillin exposure.9Digital Commons @ RU. Mode of Action of Penicillin in Pneumococci: From Inhibition of Cellular Targets to Bacterial Death In Staphylococcus aureus, the autolysin products become activated at sites where new cross-wall formation has been disrupted by penicillin, creating localized defects that spread into full-blown autolysis.10PubMed Central. Localized perforation of the cell wall by a major autolysin: atl gene products and the onset of penicillin-induced lysis of Staphylococcus aureus
Recent research has complicated this picture further. Beyond the mechanical loss of wall integrity, beta-lactams also appear to disturb the cell’s central carbon metabolism, contributing to death through oxidative damage. Even when bacteria are protected from bursting by placing them in a specially balanced solution, they still die, they just do not explode.8Nature Communications. On the mechanisms of lysis triggered by perturbations of bacterial cell wall biosynthesis So penicillin’s killing power is not solely about physical rupture; metabolic chaos plays a role too.
Why Only Growing Bacteria Are Vulnerable
One of penicillin’s well-known limitations is that it mainly kills bacteria that are actively multiplying. This makes intuitive sense once you understand the mechanism: if a bacterium is not making new cell wall, there is no cross-linking step to sabotage. A dormant cell sitting quietly in a biofilm or hiding inside a host cell is not running its PBPs at full speed, so penicillin has fewer targets to jam.11PubMed. Inhibition of cell wall synthesis–is this the mechanism of action of penicillins?
This is one reason why penicillin is classified as “bactericidal” against growing cultures but can appear merely “bacteriostatic” against slow-growing or non-dividing populations. It also partly explains why some infections are difficult to clear with beta-lactams alone: bacteria that persist in a low-metabolic state can survive a course of treatment and re-emerge later. Clinicians sometimes address this by combining penicillin with drugs that work through different mechanisms, targeting bacteria regardless of their growth state.
Visible Changes Before the Cell Dies
Bacteria exposed to beta-lactams do not simply pop like overinflated balloons. Before lysis, they often undergo dramatic shape changes that are visible under a microscope. Gram-negative bacteria, for example, can elongate into long filaments, develop bulges at the site where they were about to divide, or swell into spherical forms.12PubMed. Filamentous forms of Gram-negative bacteria on microscopy: Report of a case and review of literature These morphological changes reflect the specific PBPs that are being inhibited. Blocking the PBPs involved in cell division tends to produce filaments, because the cell keeps growing in length but cannot pinch off into two daughter cells. Blocking PBPs involved in maintaining the cylindrical shape tends to produce swollen, spherical cells.
For microbiologists, these shape changes are not just curiosities. They can serve as diagnostic clues, for instance, seeing filamentous bacteria in a clinical sample can suggest that a patient’s infection involves organisms being partially suppressed by a beta-lactam antibiotic.
Why Penicillin Does Not Harm Human Cells
The reason penicillin can be taken safely by humans, despite being lethal to bacteria, is straightforward: human cells do not have peptidoglycan. In fact, no animal cell does. Peptidoglycan is a molecule unique to bacteria, which means the entire target that penicillin attacks simply does not exist in the human body.13PubMed Central. Breaking down the cell wall: Still an attractive antibacterial strategy This gives penicillin what pharmacologists call “selective toxicity,” the ability to harm the pathogen while leaving the host largely unaffected.2Molecular Medical Microbiology. Antibiotics that Act on the Cell Wall and Membrane
That selectivity is a big part of why cell-wall-targeting antibiotics have remained a cornerstone of medicine for decades. Many other antibiotic classes target processes that human cells also perform, like protein synthesis or DNA replication, which means they have to rely on subtle differences between the bacterial and human versions of those processes. Penicillin does not need that nuance: its target is categorically absent from the host.
Penicillin Allergy Is a Different Story
If penicillin is so selective, why do some people have allergic reactions to it? The answer has nothing to do with the drug acting on human cells the way it acts on bacteria. Instead, it is about the immune system treating penicillin itself as a foreign invader. Penicillin is a small, reactive molecule. In the body, it can bind to circulating proteins, forming a new molecular structure that the immune system does not recognize.14PubMed. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy
In people who develop penicillin allergy, the immune system mounts a response against these penicillin-protein complexes. On a first exposure, the body may quietly produce antibodies. On a subsequent exposure, those antibodies are already waiting. They bind to the penicillin-protein complex and trigger mast cells to release the chemical signals responsible for allergic symptoms, from rashes to, in rare cases, life-threatening anaphylaxis.15Primary Care: Clinics in Office Practice. Penicillin allergy The allergy is a problem of immunological overreaction, not a failure of the drug’s selectivity for bacterial targets.
How Bacteria Resist Penicillin
If penicillin’s mechanism sounds foolproof, bacteria have had billions of years to find workarounds, and they have found several. Understanding how they resist helps explain why penicillin does not work against every infection.
The most common resistance strategy is producing enzymes called beta-lactamases. These enzymes grab the penicillin molecule and break open its beta-lactam ring, the very structure that mimics D-alanyl-D-alanine and jams the PBP active site. Once the ring is broken, the drug is inactivated. The interaction between a beta-lactamase and penicillin actually resembles the interaction between a PBP and penicillin, but with a critical difference: the beta-lactamase can release the drug after destroying it, treating the antibiotic as something to be processed and discarded rather than something to bind permanently.16PubMed Central. β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates
A second strategy is to alter the target itself. MRSA, or methicillin-resistant Staphylococcus aureus, is the most infamous example. These bacteria produce a modified penicillin-binding protein called PBP2a, which can still carry out the transpeptidation needed to cross-link the cell wall but whose active site resists being jammed by beta-lactam antibiotics.17PubMed Central. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function The bacterium essentially swaps out its vulnerable lock for one that the key no longer fits.
A third set of defenses involves controlling how much drug gets inside the cell in the first place. Gram-negative bacteria have an outer membrane that penicillin must cross through channel proteins called porins. Mutations that narrow or reduce the number of porins can slow the influx of the drug. Some bacteria also ramp up efflux pumps, molecular machines that actively pump the antibiotic back out of the cell before it reaches its target.18PubMed Central. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance In many resistant strains, two or even all three of these strategies work together, making the bacteria extraordinarily difficult to treat.
Fighting Back Against Resistance
Pharmacologists have not been idle while bacteria evolved resistance. One of the most successful countermeasures is pairing a beta-lactam antibiotic with a beta-lactamase inhibitor, a molecule that disables the bacterial enzyme that would otherwise destroy the drug. Clavulanic acid, for example, binds to serine beta-lactamases and forms a stable complex with them, preventing the enzyme from breaking down the accompanying antibiotic.19ChemBioChem. How Clavulanic Acid Inhibits Serine β-Lactamases The combination of amoxicillin plus clavulanic acid is one of the most widely prescribed antibiotics in the world.
The other major approach has been to design semi-synthetic penicillins and related beta-lactams whose chemical structures are harder for beta-lactamases to attack or that bind more effectively to altered PBPs. Methicillin itself was one of the earliest such modifications, created specifically to resist the beta-lactamases that were already rendering natural penicillin ineffective in the 1950s. The ongoing arms race between resistant bacteria and new drug designs continues to drive research into novel beta-lactam structures and entirely new classes of cell-wall-targeting agents.
Gram-Positive Versus Gram-Negative Bacteria
Penicillin’s effectiveness varies dramatically depending on the type of bacterium it encounters, and the distinction between Gram-positive and Gram-negative species is central to understanding why. Gram-positive bacteria have a thick peptidoglycan layer directly exposed at the cell surface, making it relatively accessible. Natural penicillin (penicillin G) works well against many Gram-positive pathogens for this reason.
Gram-negative bacteria, on the other hand, have a thinner peptidoglycan layer sandwiched between an inner membrane and an outer membrane. That outer membrane acts as an additional physical barrier. Penicillin has to pass through porin channels to reach the peptidoglycan layer and the PBPs embedded in the inner membrane. This is part of why natural penicillin has limited activity against many Gram-negative infections, and why broader-spectrum beta-lactams like ampicillin and the cephalosporins were developed to better penetrate the Gram-negative envelope. Even so, Gram-negative bacteria have more resistance tools at their disposal: the outer membrane restricts drug entry, efflux pumps sit ready to expel it, and beta-lactamases are often concentrated in the space between the two membranes, right where they can intercept the drug before it reaches a PBP.18PubMed Central. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance
Why the Cell Wall Remains a Prime Drug Target
Despite decades of resistance evolution, the bacterial cell wall remains one of the most attractive targets for antibiotic development. The fundamental reason is the selectivity advantage mentioned earlier: because peptidoglycan has no counterpart in human biology, drugs aimed at it are inherently less likely to cause toxic side effects in patients.13PubMed Central. Breaking down the cell wall: Still an attractive antibacterial strategy That is a practical advantage that is hard to overstate. Many candidate antibiotics fail in development not because they cannot kill bacteria but because they also harm human cells. Targeting a structure that humans simply do not have sidesteps much of that problem.
Researchers are also exploring newer approaches to wall disruption beyond classic beta-lactams. Some are developing drugs that target different steps in peptidoglycan synthesis, upstream of the transpeptidation step where penicillin acts. Others are investigating ways to interfere with the regulation of autolysins, essentially turning the bacterium’s own wall-recycling machinery against it. The ongoing interest reflects a broader reality: for all the worry about antibiotic resistance, the cell wall is still a genuinely vulnerable point in bacterial biology, and there is still room for new chemistry to exploit it.